TOP POSTER
Types and Prevalence of Adverse Skin Reactions Associated With N95 and Simple Mask Usage during the COVID-19 Pandemic
Ariel Darnall, DO
Types and Prevalence of Adverse Skin Reactions Associated With N95 and Simple Mask Usage during the COVID-19 Pandemic
Ariel Darnall, DO
Characteristics and Treatment of GPP Flares in the US
Zema CL, Valdecantos WC, Weiss J, Krebs B, Menter AM
Zema CL, Valdecantos WC, Weiss J, Krebs B, Menter AM
Comparison of GPP patients With and Without Documented Flare Episodes in Their Medical Record
Zema CL, Valdecantos WC, Weiss J, Krebs B, Menter AM
Zema CL, Valdecantos WC, Weiss J, Krebs B, Menter AM
Medication Use During Hospitalizations for Generalized Pustular Psoriasis
Zema CL, Valdecantos WC, Weiss J, Krebs B, Menter AM,
Zema CL, Valdecantos WC, Weiss J, Krebs B, Menter AM,
Appropriate utilization of the prognostic 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma (cSCC) demonstrated by clinical reports and physician evaluation of real-world cases
Aaron S. Farberg, PhD, Jennifer J. Siegel, PhD, Briana Rackley, PhD, Alison L. Fitzgerald, PhD, Sonia K. Morgan-Linnell, Sarah J. Kurley
Aaron S. Farberg, PhD, Jennifer J. Siegel, PhD, Briana Rackley, PhD, Alison L. Fitzgerald, PhD, Sonia K. Morgan-Linnell, Sarah J. Kurley
The 31-gene expression profile test stratifies patient risk of recurrence and metastasis in patients with a negative sentinel lymph node biopsy
Brian Martin, Jennifer J. Siegel, Sonia K. Linnell Morgan
Brian Martin, Jennifer J. Siegel, Sonia K. Linnell Morgan
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
Richard Warren, April Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup, Sudeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt
Richard Warren, April Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup, Sudeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt
POSTER OF THE DAY - FRIDAY, MARCH 11, 2022
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo in Scalp, Nail, and Palmoplantar Psoriasis: Subset Analyses of the Phase 3 POETYK PSO-1 and PSO-2 Trials
Richard Warren, April Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup, Sudeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo in Scalp, Nail, and Palmoplantar Psoriasis: Subset Analyses of the Phase 3 POETYK PSO-1 and PSO-2 Trials
Richard Warren, April Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup, Sudeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt
Deucravacitinib Long-term Safety in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO Program
Richard B Warren, Howard Sofen, Shinichi Imafuku, Jacek C Szepietowski, Andrew Blauvelt, Lynda Spelman, Jessica Toms, Alex Buck, Subhashis Banerjee, Alan Menter
Richard B Warren, Howard Sofen, Shinichi Imafuku, Jacek C Szepietowski, Andrew Blauvelt, Lynda Spelman, Jessica Toms, Alex Buck, Subhashis Banerjee, Alan Menter
POSTER OF THE DAY - SUNDAY, MARCH 13, 2022
Safety and Efficacy of Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, for the Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials
Mark Lebwohl, Leon H. Kircik, Angela Y. Moore, Linda Stein Gold, James Del Rosso, Zoe D. Draelos, Melinda J. Gooderham, Lawrence J. Green, Adelaide A. Hebert, Kim A. Papp, Jerry Bagel, Neal Bhatia, Laura K. Ferris, Terry Jones, Steven E. Kempers, David M. Pariser, Paul S. Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert C. Higham, David R. Berk
Safety and Efficacy of Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, for the Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials
Mark Lebwohl, Leon H. Kircik, Angela Y. Moore, Linda Stein Gold, James Del Rosso, Zoe D. Draelos, Melinda J. Gooderham, Lawrence J. Green, Adelaide A. Hebert, Kim A. Papp, Jerry Bagel, Neal Bhatia, Laura K. Ferris, Terry Jones, Steven E. Kempers, David M. Pariser, Paul S. Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert C. Higham, David R. Berk
Patient-reported symptom relief from the Week 28 interim analysis of a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis
J Gabriel Vasquez, Neal Bhatia, Paulita Beute, Monique Torres, Brad Schenkel, Stephen J Rozzo, Jayme Heim1
J Gabriel Vasquez, Neal Bhatia, Paulita Beute, Monique Torres, Brad Schenkel, Stephen J Rozzo, Jayme Heim1
Patient satisfaction with tildrakizumab treatment in the Week 28 interim analysis of a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis
Jayme Heim, J Gabriel Vasquez, Paulita Beute, Monique Torres, Brad Schenkel, Stephen J Rozzo, Neal Bhatia
Jayme Heim, J Gabriel Vasquez, Paulita Beute, Monique Torres, Brad Schenkel, Stephen J Rozzo, Neal Bhatia
Efficacy and safety of 1% clascoterone cream through 12 weeks in patients ≥12 years of age with facial acne vulgaris: pooled data analyses of two Phase 3 randomized clinical trials
Martina Cartwright, Luigi Moro, Enrico Fragasso, Jenny Han, Nicholas Squittieri, Alessandro Mazzetti
Martina Cartwright, Luigi Moro, Enrico Fragasso, Jenny Han, Nicholas Squittieri, Alessandro Mazzetti
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials
Leon Kircik, MD, Linda Stein Gold, MD, James Del Rosso, DO, Seemal R. Desai, MD, Brad P. Glick, DO, Howard Sofen, MD, Anna M. Tallman, PharmD, David S. Rubenstein, MD, PhD, Janine Fournier, PharmD, Philip M. Brown, MD, JD
Leon Kircik, MD, Linda Stein Gold, MD, James Del Rosso, DO, Seemal R. Desai, MD, Brad P. Glick, DO, Howard Sofen, MD, Anna M. Tallman, PharmD, David S. Rubenstein, MD, PhD, Janine Fournier, PharmD, Philip M. Brown, MD, JD
Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial
Jerry Bagel, MD, Linda Stein Gold, MD, James Del Rosso, DO, Neal Bhatia, MD, Sandy Johnson, MD, Paul Yamauchi, MD, PhD, Angela Y. Moore, MD, Anna M. Tallman, PharmD
Jerry Bagel, MD, Linda Stein Gold, MD, James Del Rosso, DO, Neal Bhatia, MD, Sandy Johnson, MD, Paul Yamauchi, MD, PhD, Angela Y. Moore, MD, Anna M. Tallman, PharmD
Efficacy and Safety of Dupilumab in Children Aged ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis
Amy S. Paller, MD, Elaine C. Siegfried, MD, Eric L. Simpson, MD, Andreas Wollenberg, MD, Mercedes E. Gonzalez, MD, Robert Sidbury, MD, Benjamin Lockshin, MD, Yiping Sun, PhD, John T. O’Malley, MD, Ashish Bansal, MD
Amy S. Paller, MD, Elaine C. Siegfried, MD, Eric L. Simpson, MD, Andreas Wollenberg, MD, Mercedes E. Gonzalez, MD, Robert Sidbury, MD, Benjamin Lockshin, MD, Yiping Sun, PhD, John T. O’Malley, MD, Ashish Bansal, MD
Long-Term Safety Data for Dupilumab up to 4 Years in an Open-Label Extension Study of Adults With Moderate-to-Severe Atopic Dermatitis
Melinda Gooderham, MD, Andreas Wollenberg, MD, Weily Soong MD, Robert Bissonnette, MD, Jing Xiao, PhD, Faisal A. Khokhar, MD, Ainara Rodríguez Marco, MD, Noah A. Levit, MD, Arsalan Shabbir, MD
Melinda Gooderham, MD, Andreas Wollenberg, MD, Weily Soong MD, Robert Bissonnette, MD, Jing Xiao, PhD, Faisal A. Khokhar, MD, Ainara Rodríguez Marco, MD, Noah A. Levit, MD, Arsalan Shabbir, MD
Dupilumab Provides Long-Term Improvement in Sleep Loss in Children, Adolescents, and Adults With Atopic Dermatitis
Mette Deleuran MD, Eric L. Simpson, MD, Amy Praestgaard, MD, Haixin Zhang, Zhixiao Wang, PhD, Ana B. Rossi, MD
Mette Deleuran MD, Eric L. Simpson, MD, Amy Praestgaard, MD, Haixin Zhang, Zhixiao Wang, PhD, Ana B. Rossi, MD
Dupilumab Monotherapy Provides Long-Term Control and Prevents Flares in Adults With Moderate-to-Severe Atopic Dermatitis Optimally Responding at Week 16
Andreas Wollenberg, MD, Diamant Thaçi, MD, Margitta Worm, MD, Eric L. Simpson, MD, Robert Bissonnette, MD, Amy Praestgaard, MD, Gerald Wilson, PharmD, Ana B. Rossi, MD
Andreas Wollenberg, MD, Diamant Thaçi, MD, Margitta Worm, MD, Eric L. Simpson, MD, Robert Bissonnette, MD, Amy Praestgaard, MD, Gerald Wilson, PharmD, Ana B. Rossi, MD
Efficacy of spesolimab for the rapid control of generalized pustular psoriasis flares: Results from the placebo-controlled Effisayil 1 study
Hervé Bachelez, Jonathan Barker, Kamran Ghoreschi, Boni E. Elewski, Jinhua Xu, Na Hu, Manuel Quaresma, Christian Thoma, Mark G. Lebwohl
Hervé Bachelez, Jonathan Barker, Kamran Ghoreschi, Boni E. Elewski, Jinhua Xu, Na Hu, Manuel Quaresma, Christian Thoma, Mark G. Lebwohl
Insights from patients with generalized pustular psoriasis (GPP): Results of an online survey in the USA
Nirali Kotowsky, Steven R. Brunette, Wendell C. Valdecantos
Nirali Kotowsky, Steven R. Brunette, Wendell C. Valdecantos
COVID-19 in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: case series from the ECZTEND long-term extension trial
Andrew Blauvelt, Andrew Pink, Margitta Worm, Richard Langley, Antonio Costanzo, Le Gjerum, Emilie Jorgensen, Joshua Corriveau, Emma Guttman-Yassky
Andrew Blauvelt, Andrew Pink, Margitta Worm, Richard Langley, Antonio Costanzo, Le Gjerum, Emilie Jorgensen, Joshua Corriveau, Emma Guttman-Yassky
Long-term treatment with tralokinumab normalizes the molecular gene signature of atopic dermatitis
Emma Guttman-Yassky, Ana Pavel, Kenji Kabashima, Delphine Staumont-Salle, Kilian Eyerich, Walter Nahm, Sylvia Pauser, Joel Correa Da Rosa, Mads Roepke, Petra Amoudruz, Andrew Blauvelt, Kristian Reich
Emma Guttman-Yassky, Ana Pavel, Kenji Kabashima, Delphine Staumont-Salle, Kilian Eyerich, Walter Nahm, Sylvia Pauser, Joel Correa Da Rosa, Mads Roepke, Petra Amoudruz, Andrew Blauvelt, Kristian Reich
POSTER OF THE DAY - SATURDAY, MARCH 12, 2022
Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial
Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie L.A. Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric L. Simpson
Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial
Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie L.A. Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric L. Simpson
Tralokinumab treatment substantially improves patient-reported outcomes in adolescents with moderate-to-severe atopic dermatitis at 16 weeks
Weily Soong, Andrew Blauvelt, Andreas Wollenberg, Chih-ho Hong, Jeffrey Leflein, Anthony Bewley, Petra Amoudruz, Marie Holst Moerch, Lise Soldbro, Shannon Schneider, Eric L. Simpson, Amy Paller
Weily Soong, Andrew Blauvelt, Andreas Wollenberg, Chih-ho Hong, Jeffrey Leflein, Anthony Bewley, Petra Amoudruz, Marie Holst Moerch, Lise Soldbro, Shannon Schneider, Eric L. Simpson, Amy Paller
Bimekizumab versus ustekinumab in plaque psoriasis: Efficacy translates to sustained improvements in quality of life in the BE VIVID multicentre, randomised, double-blinded phase 3 trial
Peter Foley, Kenneth B. Gordon, Shinichi Imafuku, Joseph F. Merola, Katy White, Veerle Vanvoorden, Fabienne Staelens, Valerie Ciaravino, Mamitaro Ohtsuki
Peter Foley, Kenneth B. Gordon, Shinichi Imafuku, Joseph F. Merola, Katy White, Veerle Vanvoorden, Fabienne Staelens, Valerie Ciaravino, Mamitaro Ohtsuki
Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled results from three multicentre, randomised, double blinded phase 3 trials
Lynda Spelman, Richard B. Warren, Bruce Strober, Pablo Fernandez-Peñas, Luke Peterson, Christopher Cioffi, Cynthia Madden, Mamitaro Ohtsuki
Lynda Spelman, Richard B. Warren, Bruce Strober, Pablo Fernandez-Peñas, Luke Peterson, Christopher Cioffi, Cynthia Madden, Mamitaro Ohtsuki
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 52-Week Results From KEEPsAKE 1
Lars Erik Kristensen , Mauro Keiserman , Kim Papp , Leslie McCasland , Douglas White , Wenjing Lu , Ahmed M Soliman , Ann Eldred , Lisa Barcomb, Frank Behrens
Lars Erik Kristensen , Mauro Keiserman , Kim Papp , Leslie McCasland , Douglas White , Wenjing Lu , Ahmed M Soliman , Ann Eldred , Lisa Barcomb, Frank Behrens
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 52-Week Results From KEEPsAKE 2
Andrew Östör , Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Byron Padilla, Alan Kivitz
Andrew Östör , Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Byron Padilla, Alan Kivitz
Long-Term Efficacy and Safety of Risankizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: Interim Analysis of the LIMMitless Open-Label Extension Trial Beyond 3.5 Years of Follow-Up
Kim A Papp, Mark G Lebwohl, Lluís Puig, Mamitaro Ohtsuki, Stefan Beissert, Jiewei Zeng, Simone Rubant, Ranjeeta Sinvhal, Ahmed M Soliman, Stefan Beeck, Craig Leonardi
Kim A Papp, Mark G Lebwohl, Lluís Puig, Mamitaro Ohtsuki, Stefan Beissert, Jiewei Zeng, Simone Rubant, Ranjeeta Sinvhal, Ahmed M Soliman, Stefan Beeck, Craig Leonardi
Early Ocular Involvement in Granulomatosis with Polyangiitis
Caroline Brailsford, MS; Chelsea Shope, BA; Laura Andrews, BS; India Robinson, BA; Alan Snyder, MD, MSCR; Lara Wine Lee, MD, PhD
Caroline Brailsford, MS; Chelsea Shope, BA; Laura Andrews, BS; India Robinson, BA; Alan Snyder, MD, MSCR; Lara Wine Lee, MD, PhD
TOP POSTER
Epidemiological Insight into Acrodermatitis Continua of Hallopeau for Early Diagnosis and Prevention of Disease Progression
Thao Pham, DO; Leon Clark, MD
Epidemiological Insight into Acrodermatitis Continua of Hallopeau for Early Diagnosis and Prevention of Disease Progression
Thao Pham, DO; Leon Clark, MD
Personalized Medicine for Psoriasis Biologic Treatment
Tobin J. Dickerson, PhD, Byung-In Lee, PhD, Paul Montgomery III, MS, Stephen Boyd, BS, Eric Andrade, BS, Christian Abaya, BS, Courtney Boyce, BS, Tatiana Tomich, MPH, and Yipeng Wang, MD, PhD
Tobin J. Dickerson, PhD, Byung-In Lee, PhD, Paul Montgomery III, MS, Stephen Boyd, BS, Eric Andrade, BS, Christian Abaya, BS, Courtney Boyce, BS, Tatiana Tomich, MPH, and Yipeng Wang, MD, PhD
Dermatologist Concordance with a Precision Medicine Test for the Selection of Psoriasis Biologic Treatment
Bruce E. Strober, MD, PhD, Anish Kunder, Courtney Boyce, Paul Montgomery III, Ann Deren-Lewis, and Tobin J. Dickerson, PhD
Bruce E. Strober, MD, PhD, Anish Kunder, Courtney Boyce, Paul Montgomery III, Ann Deren-Lewis, and Tobin J. Dickerson, PhD
